Association between Serum Biomarkers with Postoperative Complications and Delay of Adjuvant Chemotherapy Initiation in Ovarian Cancer Patients Undergoing Primary Cytoreductive Surgery: A Pilot Study

References

• Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80(7):1273–83.
   PubMed Web of Science ®Google Scholar
• Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, Williams S. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993;71(2 Suppl):606–14.
   PubMed Web of Science ®Google Scholar
• Matsuda A, Katanoda K. Five-year relative survival rate of ovarian cancer in the USA, Europe and Japan. Jpn J Clin Oncol. 2014;44(2):196. doi: 10.1093/jjco/hyu007.
   PubMedGoogle Scholar
• Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–29. doi: 10.1056/NEJMra041842.
   PubMed Web of Science ®Google Scholar
• Morgan RJ, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen L-M, Copeland L, Crispens MA, DeRosa M, Dorigo O, et al. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(9):1134–63.
   PubMed Web of Science ®Google Scholar
• Uyar D, Frasure HE, Markman M, von Gruenigen VE. Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer. Gynecol Oncol. 2005;98(3):403–8. doi: 10.1016/j.ygyno.2005.04.037.
   PubMed Web of Science ®Google Scholar
• Ries LA. Ovarian cancer. Survival and treatment differences by age. Cancer. 1993;71(2 Suppl):524–9.
   PubMed Web of Science ®Google Scholar
• Hightower RD, Nguyen HN, Averette HE, Hoskins W, Harrison T, Steren A. National survey of ovarian carcinoma. IV: patterns of care and related survival for older patients. Cancer. 1994;73(2):377–83.
   PubMed Web of Science ®Google Scholar
• Cress RD, O'Malley CD, Leiserowitz GS, Campleman SL. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol. 2003;21(8):1530–5. doi: 10.1200/JCO.2003.08.065.
   PubMed Web of Science ®Google Scholar
• Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31. doi: 10.1016/j.ygyno.2009.03.018.
   PubMed Web of Science ®Google Scholar
• Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124(1):10–4. doi: 10.1016/j.ygyno.2011.08.014.
   PubMed Web of Science ®Google Scholar
• Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, Hamilton CA, Krivak TC, Maxwell GL. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015;33(8):937–43. doi: 10.1200/JCO.2014.56.3106.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi: 10.3322/caac.21254.
   PubMed Web of Science ®Google Scholar
• Monfardini S, Chabner B. Joint NCI-EORTC consensus meeting on neoplasia in the elderly. San Servolo Island, Venice, 15–16 October 1990. Eur J Cancer. 1991;27(5):653–4.
   PubMed Web of Science ®Google Scholar
• Miyaishi O, Ando F, Matsuzawa K, Kanawa R, Isobe K. Cancer incidence in old age. Mech Ageing Dev. 2000;117(1-3):47–55.
   PubMed Web of Science ®Google Scholar
• Singh S, Guetzko M, Resnick K. Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer. Gynecol Oncol. 2016;143(2):241–5. doi: 10.1016/j.ygyno.2016.09.004.
   PubMed Web of Science ®Google Scholar
• Seagle BL, Butler SK, Strohl AE, Nieves-Neira W, Shahabi S. Chemotherapy delay after primary debulking surgery for ovarian cancer. Gynecol Oncol. 2017;144(2):260–5. doi: 10.1016/j.ygyno.2016.11.022.
   PubMed Web of Science ®Google Scholar
• Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol. 2016;27(1):114–21. doi: 10.1093/annonc/mdv500.
   PubMed Web of Science ®Google Scholar
• Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T, Trillsch F, Mahner S, Ulmer H, et al. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma – analysis of patient data in the prospective OVCAD study. Gynecol Oncol. 2013;131(1):15–20. doi: 10.1016/j.ygyno.2013.07.086.
   PubMed Web of Science ®Google Scholar
• Mahner S, Eulenburg C, Staehle A, Wegscheider K, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J, Du Bois A, et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer. 2013;49(1):142–9. doi: 10.1016/j.ejca.2012.07.023.
   PubMed Web of Science ®Google Scholar
• Hatse S, Lambrechts D, Verstuyf A, Smeets A, Brouwers B, Vandorpe T, Brouckaert O, Peuteman G, Laenen A, Verlinden L, et al. Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis. 2012;33(7):1319–26. doi: 10.1093/carcin/bgs187.
   PubMed Web of Science ®Google Scholar
• McCullough ML, Bandera EV, Moore DF, Kushi LH. Vitamin D and calcium intake in relation to risk of endometrial cancer: a systematic review of the literature. Prev Med. 2008;46(4):298–302. doi: 10.1016/j.ypmed.2007.11.010.
   PubMed Web of Science ®Google Scholar
• Zgaga L, Theodoratou E, Farrington SM, Din FVN, Ooi LY, Glodzik D, Johnston S, Tenesa A, Campbell H, Dunlop MG, et al. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J Clin Oncol. 2014;32(23):2430–9. doi: 10.1200/JCO.2013.54.5947.
   PubMed Web of Science ®Google Scholar
• Reis LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (eds). SEER Cancer Statistics Review, 1973–1999, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1973_1999/, 2002.
   Google Scholar
• Charehbili A, Hamdy NAT, Smit VTHBM, Kessels L, van Bochove A, van Laarhoven HW, Putter H, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van der Hoeven JJM, Dutch Breast Cancer Research Group (BOOG), et al. Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: data from the NEOZOTAC trial (BOOG 10-01). Breast. 2016;25:69–74. doi: 10.1016/j.breast.2015.10.005.
   PubMed Web of Science ®Google Scholar
• Krishnan AV, Swami S, Feldman D. The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. Steroids. 2012;77(11):1107–12. doi: 10.1016/j.steroids.2012.06.005.
   PubMed Web of Science ®Google Scholar
• Webb PM, de Fazio A, Protani MM, Ibiebele TI, Nagle CM, Brand AH, Blomfield PI, Grant P, Perrin LC, Neale RE, Australian Ovarian Cancer Study Group, et al. Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer. Am J Clin Nutr. 2015;102(1):109–14. doi: 10.3945/ajcn.114.102681.
   PubMed Web of Science ®Google Scholar
• Urban RR, He H, Alfonso R, Hardesty MM, Gray HJ, Goff BA. Ovarian cancer outcomes: predictors of ­early death. Gynecol Oncol. 2016;140(3):474–80. doi: 10.1016/j.ygyno.2015.12.021.
   PubMed Web of Science ®Google Scholar
• Cliby WA, Powell MA, Al-Hammadi N, Chen L, Philip Miller J, Roland PY, Mutch DG, Bristow RE. Ovarian cancer in the United States: contemporary patterns of care associated with improved survival. Gynecol Oncol. 2015;136(1):11–7. doi: 10.1016/j.ygyno.2014.10.023.
   PubMed Web of Science ®Google Scholar
• Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR, Goff BA. Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. Gynecol Oncol. 2011;122(1):100–6. doi: 10.1016/j.ygyno.2011.03.022.
   PubMed Web of Science ®Google Scholar
• Sanguinete MMM, Oliveira PHD, Martins-Filho A, Micheli DC, Tavares-Murta BM, Murta EFC, Nomelini RS. Serum IL-6 and IL-8 correlate with prognostic factors in ovarian cancer. Immunol Invest. 2017;46(7):677–88. doi: 10.1080/08820139.2017.1360342.
   PubMed Web of Science ®Google Scholar
• Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 2011;11(1):210. doi: 10.1186/1471-2407-11-210.
   PubMedGoogle Scholar
• Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, Nozawa S, Furukawa K, Mitsuhashi N, Sawada S, et al. Increased plasma levels of IL-6 and IL-8 are associated with surgical site infection after pancreaticoduodenectomy. Pancreas. 2006;32(2):178–85. doi: 10.1097/01.mpa.0000202959.63977.5c.
   PubMed Web of Science ®Google Scholar
• Ortiz-Montero P, Londono-Vallejo A, Vernot JP. Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line. Cell Commun Signal. 2017;15(1):17. doi: 10.1186/s12964-017-0172-3.
   PubMed Web of Science ®Google Scholar
• Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197:676 e1–7. doi: 10.1016/j.ajog.2007.10.495.
   PubMed Web of Science ®Google Scholar
• Kumar A, Janco JM, Mariani A, Bakkum-Gamez JN, Langstraat CL, Weaver AL, McGree ME, Cliby WA. Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. Gynecol Oncol. 2016;140(1):15–21. doi: 10.1016/j.ygyno.2015.10.025.
   PubMed Web of Science ®Google Scholar
• Wright JD, Herzog TJ, Neugut AI, Burke WM, Lu Y-S, Lewin SN, Hershman DL. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Obstet Gynecol. 2012; 120(4):871–81. doi: 10.1097/Aog.0b013e31826981de.
   PubMed Web of Science ®Google Scholar
• Thrall MM, Goff BA, Symons RG, Flum DR, Gray HJ. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol. 2011;118(3):537–47. doi: 10.1097/AOG.0b013e31822a6d56.
   PubMed Web of Science ®Google Scholar
• Tahiri M, Sikder T, Maimon G, Teasdale D, Hamadani F, Sourial N, Feldman LS, Guralnick J, Fraser SA, Demyttenaere S, et al. The impact of postoperative complications on the recovery of elderly surgical patients. Surg Endosc. 2016;30(5):1762–70. doi: 10.1007/s00464-015-4440-2.
   PubMed Web of Science ®Google Scholar